6505--Notice of Intent - Sole Source for Pluvicto
Contract Opportunity Analysis
The Department of Veterans Affairs (VA) intends to award a sole source contract for the procurement of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) from Novartis Pharmaceuticals Corporation. This highly specialized radiopharmaceutical is required for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have undergone prior treatments. The contract will be executed by the VA Northern California Health Care System located in Mather, California, and is crucial for providing effective therapeutic options for eligible patients. Interested parties may submit written notice to Victoria Torres at victoria.torres@va.gov by 5:00 PM PDT on September 17, 2025, to demonstrate their capability to meet the requirement, although this notice does not constitute a request for competitive proposals.